NDA 200535 · Genus Lifesciences
Oxycodone Hydrochloride
Oxycodone Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Oct 20, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
646
137 Phase 3, 50 recruiting
FAERS reports
186,853
153,019 serious, 53,601 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HYDROCHLORIDE ORAL SOLUTION Risk of Medication Errors Ensure accuracy when prescribing, dispensing, and administering Oxycodone Hydrochloride Oral Solution. Dosing errors due to confusion between mg and mL, and other oxycodone hydrochloride oral solutions of different concentrations can result in accidental overdose and death [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) ] . Addiction, Abuse, and Misuse Because the use of Oxycodone Hydrochloride Oral Solution exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.2) ] . Life-Threatening Respiratory Depression...
What it is approved for
From the label in effect Apr 16, 2026.
Oxycodone Hydrochloride Oral Solution is indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone Hydrochloride Oral Solution 100 mg per 5 mL (20 mg/mL) is indicated for use in opioid-tolerant adult patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration, and persist over the course of therapy [see Warnings and Precautions (5.2) ] , reserve opioid analgesics, including Oxycodone Hydrochloride Oral Solution, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Oxycodone Hydrochloride Oral Solution is an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Oxycodone Hydrochloride Oral Solution 100 mg per 5 mL (20 mg/mL) is indicated for use in opioid-tolerant adult patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, overdose, and death, with opioids, which can occur at any dosage or duration, and persist over the course of therapy, reserve opioid analgesics, including Oxycodone Hydrochloride Oral Solution, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate...
Mechanism: Oxycodone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 21, 2021 Supplement 17 · Efficacy LetterLabel
- Oct 20, 2010 Original approval · Type 7 - Drug Already Marketed without Approved NDA LabelReviewSummary Review
2 products under this application
- OXYCODONE HYDROCHLORIDE · OXYCODONE HYDROCHLORIDE 100MG/5ML · SOLUTION, ORAL · Prescription · TE AA
- OXYCODONE HYDROCHLORIDE · OXYCODONE HYDROCHLORIDE 5MG/5ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxycodone" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Opioid Prescription After Cesarean TrialPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT04296396 · 5,521 participants · Start Sep 21, 2020 · Primary completion Apr 7, 2022
Drug: 0 to 20 tablets of oxycodone 5mg; Fixed opioid prescription · For: Pregnancy Related; Opioid Use; Pain
Sites: Birmingham, Alabama; Chicago, Illinois; New York, New York · 12 sites in all
- Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer PainPivotal-lookingCompleted
Gachon University Gil Medical CenterAcademic, hospital or other
NCT00478101 · 2,006 participants · Start Feb 2006
Drug: oxycodone fentanyl · For: Advanced Solid Cancers
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Determining the Effect of an "Alternate Recovery Protocol" Versus Current Standard of Care After Cesarean SectionPivotal-lookingTerminated
Brest, Norman A., M.D.Academic, hospital or other
NCT03330119 · 1,494 participants · Start Oct 4, 2017 · Primary completion Jun 20, 2018
Drug: Alternate Management; Control · For: Pregnancy Related; Narcotic Use
Sites: Wynnewood, Pennsylvania
- Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Post-operative PainPivotal-lookingNot yet recruiting
Ailin LuoAcademic, hospital or other
NCT06721988 · 1,316 participants (planned) · Start Jan 1, 2025 · Primary completion Dec 31, 2026
Drug: oxycodone and parecoxib sodium combinations; Placebo and parecoxib sodium combinations · For: Oxycodone; Chronic Pain, Postoperative
- A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00361504 · 1,123 participants · Start Nov 2006 · Primary completion Jul 2008
Drug: Oxycodone CR; Tapentadol (CG5503) ER · For: Osteoarthritis, Hip; Osteoarthritis, Knee; Lower Back Pain and 1 more
Sites: Mesa, Arizona; Tucson, Arizona; Anaheim, California · 52 sites in all
- Comparative Effectiveness Study for Surgery vs. Non-Surgery in Patients With Low Back PainPivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02883569 · 1,102 participants · Start Sep 2016 · Primary completion Dec 2020
Drug: ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac; codeine, oxycontine, IRcodone, Tramadol · For: Low Back Pain
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dependence27,731
- pain27,052
- death19,926
- overdose19,306
- toxicity to various agents16,584
- emotional distress15,682
- fatigue12,571
- drug ineffective11,980
- nausea11,209
- drug withdrawal syndrome10,507
- off label use8,990
- diarrhoea8,723
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 237 |
| 2005 | 356 |
| 2006 | 319 |
| 2007 | 120 |
| 2008 | 310 |
| 2009 | 1,002 |
| 2010 | 1,509 |
| 2011 | 1,375 |
| 2012 | 2,114 |
| 2013 | 4,478 |
| 2014 | 5,535 |
| 2015 | 8,351 |
| 2016 | 9,339 |
| 2017 | 11,592 |
| 2018 | 33,099 |
| 2019 | 11,654 |
| 2020 | 13,599 |
| 2021 | 20,254 |
| 2022 | 22,581 |
| 2023 | 10,915 |
| 2024 | 10,095 |
| 2025 | 10,667 |
| 2026 | 7,351 |
Recalls
1 FDA enforcement reports for this application.
Dec 23, 2020 · Class III · Terminated
Presence of Foreign Substance: Particulate matter was found in multiple lots of product.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.
Kistemaker KRJ, Sijani F, Brinkman DJ, et al. · Cancer Treat Rev 2024 · Meta-Analysis, Systematic Review
- Acute Postoperative Pain Due to Dental Extraction in the Adult Population: A Systematic Review and Network Meta-analysis.
Miroshnychenko A, Ibrahim S, Azab M, et al. · J Dent Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Shifting Views on Cancer Pain Management: A Systematic Review and Network Meta-Analysis.
Imkamp MSV, Theunissen M, Viechtbauer W, et al. · J Pain Symptom Manage 2024 · Systematic Review, Network Meta-Analysis
- Tapentadol and oxycodone reduce cingulate glutamate in healthy volunteers.
Hansen TM, Frøkjaer JB, Mark EB, et al. · Br J Clin Pharmacol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of oxycodone for postoperative dental pain: A systematic review and meta-analysis.
Teoh L, McCullough M, Taing MW · J Dent 2022 · Meta-Analysis, Systematic Review
- Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology.
Oliveira RAA, Baptista AF, Sá KN, et al. · Arq Neuropsiquiatr 2020 · Meta-Analysis, Systematic Review
Sponsor: Genus Lifesciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.